[HTML][HTML] Bibw2992 inhibitor
AW Tolcher, R Kurzrock, V Valero, R Gonzalez… - bibw2992inhibitor.com
Purpose This study aimed to determine the safety, tolerability, and recommended phase II
doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be …
doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be …
A phase I study of daily BIBW 2992, an irreversible EGFR/HER-2 dual kinase inhibitor, in combination with weekly paclitaxel
J Ang, C Mikropoulos, F Stavridi, S Rudman… - Journal of Clinical …, 2009 - ascopubs.org
e14541 Background: BIBW 2992 is an oral, potent and irreversible inhibitor of both EGFR
and HER2 receptor tyrosine kinases. The efficacy of cytotoxic agents can be enhanced by …
and HER2 receptor tyrosine kinases. The efficacy of cytotoxic agents can be enhanced by …
Cobimetinib (GDC-0973, XL518)
H Andrlová, R Zeiser, F Meiss - Small Molecules in Oncology, 2018 - Springer
The mitogen-activated protein kinase cascade (MAPK/ERK pathway) is a signaling pathway
activated as a cellular response to various stimuli and for regulating the proliferation and …
activated as a cellular response to various stimuli and for regulating the proliferation and …
Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off …
CH Mom, FA Eskens, JA Gietema, K Nooter… - Journal of Clinical …, 2006 - ascopubs.org
3025 Background: BIBW 2992 is a highly selective, potent, irreversible tyrosine inhibitor of
EGFR and HER2. A phase 1 study of orally administered BIBW 2992 was performed to …
EGFR and HER2. A phase 1 study of orally administered BIBW 2992 was performed to …
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
AW Tolcher, R Kurzrock, V Valero, R Gonzalez… - Cancer chemotherapy …, 2020 - Springer
Purpose This study aimed to determine the safety, tolerability, and recommended phase II
doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be …
doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be …
[HTML][HTML] Bms 986165 acts as a highly selective allosteric inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2). Menu
R Kainthla, KB Kim, GS Falchook - bms-986165inhibitor.com
Dabrafenib was developed as a highly specific reversible inhibitor of V600-mutant BRAF
kinase, an oncogenic mutation driving proliferation in many different types of aggressive …
kinase, an oncogenic mutation driving proliferation in many different types of aggressive …
Pharmacokinetics (PK) of [14C]-BIBW 2992 after administration of a single dose of 15 mg [14C]-BIBW 2992 oral solution in healthy male volunteers
P Stopfer, H Narjes, B Gaschler-Markefski… - Journal of Clinical …, 2008 - ascopubs.org
14607 Background: BIBW 2992 is a novel oral, potent and irreversible inhibitor of EGFR and
HER2. This study investigated the PKs and the mass balance of a single oral dose of [14C] …
HER2. This study investigated the PKs and the mass balance of a single oral dose of [14C] …
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with …
N Lewis, J Marshall, A Amelsberg… - Journal of Clinical …, 2006 - ascopubs.org
3091 Background: BIBW 2992 is a highly potent irreversible dual EGFR/HER2 receptor
tyrosine kinase inhibitor. This is the first trial performed in the United States with this …
tyrosine kinase inhibitor. This is the first trial performed in the United States with this …
Trametinib: first global approval
CJM Wright, PL McCormack - Drugs, 2013 - Springer
Trametinib is an orally bioavailable mitogen-activated protein kinase (MAPK) kinase (MEK)
inhibitor with antineoplastic activity. The compound specifically binds to MEK1 and MEK2 …
inhibitor with antineoplastic activity. The compound specifically binds to MEK1 and MEK2 …
Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of …
1023 Background: BIBW 2992 (Tovok) is an oral, novel, and potent, irreversible dual
epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 …
epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 …